Last reviewed · How we verify
JSKN016 Q3W — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
JSKN016 Q3W (JSKN016 Q3W) — Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JSKN016 Q3W TARGET | JSKN016 Q3W | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JSKN016 Q3W CI watch — RSS
- JSKN016 Q3W CI watch — Atom
- JSKN016 Q3W CI watch — JSON
- JSKN016 Q3W alone — RSS
Cite this brief
Drug Landscape (2026). JSKN016 Q3W — Competitive Intelligence Brief. https://druglandscape.com/ci/jskn016-q3w. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab